Brokers Offer Predictions for Soligenix FY2024 Earnings

Soligenix, Inc. (NASDAQ:SNGX) – Analysts at Zacks Small Cap boosted their FY2024 EPS estimates for Soligenix in a note issued to investors on Monday, November 11th. Zacks Small Cap analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings per share of ($4.65) for the year, up from their previous forecast of ($5.10). The consensus estimate for Soligenix’s current full-year earnings is ($5.10) per share.

Soligenix Stock Performance

Shares of NASDAQ:SNGX opened at $3.63 on Thursday. The firm has a 50 day simple moving average of $3.77 and a 200 day simple moving average of $4.37. Soligenix has a 52 week low of $1.83 and a 52 week high of $32.00. The company has a market cap of $9.11 million, a PE ratio of -0.48 and a beta of 1.85.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SNGX. OLD National Bancorp IN acquired a new position in Soligenix in the 2nd quarter valued at approximately $26,000. Stephens Inc. AR purchased a new position in shares of Soligenix during the 3rd quarter valued at $184,000. Finally, Armistice Capital LLC acquired a new position in shares of Soligenix in the second quarter worth $206,000. 3.60% of the stock is owned by institutional investors and hedge funds.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.